Daily Market Brief · Monday, 1 June 2026

Zhiditech (301503) acquires Fengxu International for RMB 152.29 million

Zhiditech's board unanimously approved the acquisition of Fengxu International, while *ST Quanwei (300716) warns of potential delisting due to negative profits.

71 material announcements from 55 companies

Today's market saw significant developments, particularly in acquisitions and regulatory warnings. Zhiditech Co., Ltd. (301503) made headlines with a major acquisition, while *ST Quanwei Co., Ltd. (300716) issued a risk warning regarding its stock listing.

Deals & Restructuring

  • Zhiditech Co., Ltd. (301503): The company announced the acquisition of 100% equity in Fengxu International Investment Co., Ltd. for approximately RMB 152.29 million. This decision was made during the eighth meeting of the fourth board of directors and aims to enhance Zhiditech's international strategy.
  • Juntin Hotel Co., Ltd. (301073): The company is progressing with a tender offer to acquire 29.99% of Hubei Cultural Tourism Group Co., Ltd., involving 58,315,869 shares at RMB 25.71 each.
  • Zhongfu Technology Co., Ltd. (300692): The acquisition of Junke Zhengyuan (Beijing) Drug Research Co., Ltd. is underway, with an estimated total equity value of RMB 1 billion.

Regulatory & Governance

  • Beijing E-hualu Information Technology Co., Ltd. (300212): The company is under investigation by the China Securities Regulatory Commission for information disclosure violations and announced a pre-reorganization debt claim declaration, with creditors required to submit claims by June 28, 2026.
  • *ST Quanwei Co., Ltd. (300716): The company issued a risk warning about a possible termination of its stock listing due to negative audited profits and net assets for the last fiscal year, prompting caution among investors.
  • *ST Lingnan Co., Ltd. (002717): The company reported significant risks related to its convertible bonds, including a net loss of approximately RMB 2.34 billion in 2025, raising concerns about potential delisting.

Other Notable Developments

  • Haisco Pharmaceutical Group Co., Ltd. (002653): The company's subsidiary received FDA approval for Cipepofol Injection, marking a significant milestone as the first self-innovated intravenous anesthetic from China to gain such approval.
  • Amoy Diagnostics Co., Ltd. (300685): Trading of the company's shares will be suspended due to a planned change of control by its controlling shareholder.
  • Jiangsu Hualan New Pharmaceutical Material Co., Ltd. (301093): The company approved a RMB 205 million investment by its subsidiary to enhance its business structure.
  • Hefei Hengxin Life Science and Technology Co., Ltd. (301501): The company re-signed a tripartite supervision agreement for fundraising projects, integrating funds into a new biodegradable product production base project.
  • Yunnan Tin Co., Ltd. (000960): The board approved participation in an auction for 100% equity of Chifeng Dajingzi Tin Industry Co., Ltd., aiming to enhance domestic tin smelting capacity.

Investors should monitor these developments closely as they may impact market dynamics and company valuations.

In this brief

This brief is generated by AI from English translations of SZSE filings and may contain errors. It is for information only and is not investment advice.